- In a report, Lake Street Capital says micro cap BioScrip's (BIOS +24.5%) fair value is $4.50, implying a tidy 246% upside. Positive catalysts include a new experienced and talented CEO (Daniel Greenleaf), a solid platform and "strong playbook."
- Analyst Brooks O'Neil also cites the attractiveness of the company's niche, infusion services, a $10B market in the U.S. growing at 5 - 7% per annum.
Lake Street likes BioScrip; shares ahead 25%
This was corrected on 02/28/2020 at 4:30 PM. New CEO is Daniel Greenleaf.